(NASDAQ:HOWL), WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profile WTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated […]
(NASDAQ:APWC), TAIPEI, Taiwan, Dec. 18, 2025 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (“APWC” or “Company”) (NASDAQ: APWC) today announced the commencement of its rights offering previously reported on August 29, 2025. In the rights offering, the Company will distribute, at no charge to its shareholders, non-transferable subscription rights to purchase additional
(NYSE MKT: VTAK), Fort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a leader in advanced electrophysiology solutions, today announced the successful implementation of LockeT and the first LockeT purchase order at Mater Private Hospital, located in Dublin, Ireland. This marks a significant milestone in the company's global expansion
(AUST:ACW.AX), SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) — Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer's disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year
(NASDAQ:FUSE),(NASDAQ:FUSEW), NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — Fusemachines Inc. (“Fusemachines” or the “Company”) (NASDAQ:FUSE), a leading provider of enterprise AI products and services, today outlined its strategic growth priorities, positioning the Company for a pivotal year in 2026, focused on disciplined execution, enterprise ROI, and responsible AI product innovation. After more than a
Nedlands, WA, Dec. 18, 2025 (GLOBE NEWSWIRE) — Australia's Leading trades insurance provider All Trades Cover has officially launched its newly-designed website from its headquarters in Nedlands, Western Australia, enhancing user experience, streamlining access to services, and reaffirming its role as the trusted tradie insurance broker for Australia's tradespeople. The upgrade aligns with the company's
New York, Dec. 18, 2025 (GLOBE NEWSWIRE) — GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY, MAAY, NUGY, SEMY, QBY, RGYY, HMYY and RTYY as shown in the table below. ETF Ticker ETF Name Distribution Frequency Distribution
(NASDAQ:EDBL),(NASDAQ:EDBLW), Company's USDA Organic Herbs Align with Shared Commitment to Freshness and Sustainability Expansion Strengthens Presence Across the Mid-Atlantic BELVIDERE, NJ, Dec. 18, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today
(NASDAQ:RVMD), REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib,
(NasdaqGM:CRMD), BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company's ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care's (USRC) use of DefenCath in adult hemodialysis